DK2160221T3 - Cykliske peptid-CXCR4-antagonister - Google Patents

Cykliske peptid-CXCR4-antagonister

Info

Publication number
DK2160221T3
DK2160221T3 DK08769524.3T DK08769524T DK2160221T3 DK 2160221 T3 DK2160221 T3 DK 2160221T3 DK 08769524 T DK08769524 T DK 08769524T DK 2160221 T3 DK2160221 T3 DK 2160221T3
Authority
DK
Denmark
Prior art keywords
cyclic peptide
cxcr4 antagonists
peptide cxcr4
antagonists
cyclic
Prior art date
Application number
DK08769524.3T
Other languages
English (en)
Inventor
Wayne David Kohn
Sheng-Bin Peng
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2160221(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2160221T3 publication Critical patent/DK2160221T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK08769524.3T 2007-05-30 2008-05-20 Cykliske peptid-CXCR4-antagonister DK2160221T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31
PCT/US2008/064177 WO2008150689A1 (en) 2007-05-30 2008-05-20 Cyclic peptide cxcr4 antagonists

Publications (1)

Publication Number Publication Date
DK2160221T3 true DK2160221T3 (da) 2011-09-19

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08769524.3T DK2160221T3 (da) 2007-05-30 2008-05-20 Cykliske peptid-CXCR4-antagonister

Country Status (33)

Country Link
US (3) US7691813B2 (da)
EP (2) EP2377579A1 (da)
JP (1) JP5358564B2 (da)
KR (2) KR101319740B1 (da)
CN (1) CN101678213B (da)
AR (1) AR066648A1 (da)
AT (1) ATE516853T1 (da)
AU (1) AU2008260326B2 (da)
BR (1) BRPI0812134A2 (da)
CA (1) CA2688574C (da)
CL (1) CL2008001467A1 (da)
CO (1) CO6241137A2 (da)
CR (1) CR11105A (da)
CY (1) CY1111815T1 (da)
DK (1) DK2160221T3 (da)
DO (1) DOP2009000270A (da)
EA (1) EA017716B1 (da)
GT (1) GT200900304A (da)
HK (1) HK1141474A1 (da)
HR (1) HRP20110551T1 (da)
IL (1) IL201685A (da)
JO (1) JO2776B1 (da)
MA (1) MA31666B1 (da)
MX (1) MX2009012952A (da)
MY (1) MY149432A (da)
NZ (1) NZ580849A (da)
PE (1) PE20090299A1 (da)
PL (1) PL2160221T3 (da)
PT (1) PT2160221E (da)
TN (1) TN2009000496A1 (da)
TW (1) TWI423987B (da)
WO (1) WO2008150689A1 (da)
ZA (1) ZA200908345B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
JPWO2012118124A1 (ja) * 2011-03-01 2014-07-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
SG195055A1 (en) * 2011-06-07 2013-12-30 Polyphor Ag Beta - hairpin peptidomimetics as cxc4 antagonists
WO2013044500A1 (zh) * 2011-09-30 2013-04-04 Cheng Yun 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
WO2018048806A1 (en) * 2016-09-06 2018-03-15 Mainline Biosciences Cxcr4 antagonists and methods of use
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
KR20230145543A (ko) * 2017-09-05 2023-10-17 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
WO2019126796A1 (en) * 2017-12-21 2019-06-27 Mainline Biosciences Llc Composition comprising a therapeutic agent and a cxcr4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Cxcr4結合性化合物もしくはその塩またはそれらと金属との錯体
CA3108450A1 (en) 2018-09-12 2020-03-19 Technische Universitat Munchen Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
EA202190755A1 (ru) 2018-09-12 2021-06-11 Технише Универзитет Мюнхен Агенты для терапии и диагностики рака
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
EP4097120A4 (en) * 2020-01-26 2024-05-01 Mainline Biosciences (Shanghai) Co., Ltd. ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF
JPWO2022138891A1 (da) * 2020-12-25 2022-06-30
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
WO2023201435A1 (en) * 2022-04-20 2023-10-26 Provincial Health Services Authority Cxcr4-targeting compounds, and methods of making and using the same
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規cxcr4アンタゴニスト
JP5308829B2 (ja) * 2006-02-27 2013-10-09 テクニッシュ ユニべルシタット ミュンヘン 癌の画像化および処置

Also Published As

Publication number Publication date
TWI423987B (zh) 2014-01-21
KR101169846B1 (ko) 2012-08-01
JP5358564B2 (ja) 2013-12-04
TW200902556A (en) 2009-01-16
CN101678213A (zh) 2010-03-24
CA2688574C (en) 2014-02-18
JP2010529957A (ja) 2010-09-02
CA2688574A1 (en) 2008-12-11
IL201685A (en) 2015-04-30
PL2160221T3 (pl) 2011-12-30
BRPI0812134A2 (pt) 2014-11-18
MA31666B1 (fr) 2010-09-01
CY1111815T1 (el) 2015-10-07
AU2008260326B2 (en) 2011-07-21
NZ580849A (en) 2012-03-30
CN101678213B (zh) 2013-11-06
HRP20110551T1 (hr) 2011-09-30
EP2377579A1 (en) 2011-10-19
ATE516853T1 (de) 2011-08-15
CL2008001467A1 (es) 2008-12-05
AR066648A1 (es) 2009-09-02
HK1141474A1 (en) 2010-11-12
GT200900304A (es) 2011-11-09
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
TN2009000496A1 (en) 2011-03-31
CR11105A (es) 2010-04-12
JO2776B1 (en) 2014-03-15
EP2160221B1 (en) 2011-07-20
PT2160221E (pt) 2011-09-12
EA200971129A1 (ru) 2010-04-30
MX2009012952A (es) 2009-12-11
PE20090299A1 (es) 2009-03-19
US7691813B2 (en) 2010-04-06
US20100130409A1 (en) 2010-05-27
WO2008150689A1 (en) 2008-12-11
MY149432A (en) 2013-08-30
KR20100003737A (ko) 2010-01-11
AU2008260326A1 (en) 2008-12-11
EP2160221A1 (en) 2010-03-10
USRE42274E1 (en) 2011-04-05
DOP2009000270A (es) 2010-01-15
US20080300177A1 (en) 2008-12-04
IL201685A0 (en) 2010-05-31
KR101319740B1 (ko) 2013-10-17
CO6241137A2 (es) 2011-01-20
EA017716B1 (ru) 2013-02-28

Similar Documents

Publication Publication Date Title
ATE516853T1 (de) Zyklische peptid-cxcr4-antagonisten
FR22C1020I2 (fr) Antagonistes de c5ar
BRPI0911743A2 (pt) "peptídeo"
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0920521A2 (pt) combinação farmacêutica
DK2443104T3 (da) Disubstituerede phthalazin-hedgehog-sti-antagonister
DK3115370T3 (da) Biologisk aktive peptider
BRPI1012728A2 (pt) uso de tripeptídeos
BRPI0810203A2 (pt) Compostos peptídeos cíclicos.
DK2799428T3 (da) Glucagon-antagonister
ZA201000776B (en) Cyclic depsipeptides
DK2364185T3 (da) Disubstituerede phthalazin-hedgehog-pathway-antagonister
BRPI1010661A2 (pt) peptídeo
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
DK2131818T3 (da) Ny doseringsform
BRPI0817835A2 (pt) Antagonistas cgrp
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
DE502007002482D1 (de) Injektor
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
DK2257534T3 (da) 3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister
FR2940520B1 (fr) Structure semiconductrice
FI20075483A0 (fi) Uusi peptidi
DK2081952T3 (da) Peptider
FI20061156A0 (fi) Uusia peptidejä
SI2160221T1 (sl) Antagonisti cikličnih peptidov cxcr4